Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...

PSMA-PET imaging technology is leveraged to identify advanced prostate cancer. Credit: Korawat photo shoot / Shutterstock. Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.

Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

Symptoms of prostate cancer may include needing to urinate more frequently; having to rush to the toilet; straining to ...

Illuccix® is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil. Illuccix®, after radiolabeling with 68Ga, is a radioactive diagnostic agent ...

Historically, more prostate cancer patients have had a prostatectomy than any other treatment, since radiation as an ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment ...